Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study
Authors
Abstract:
A 65 year old male with metastatic colorectal cancer (mCRC) in the liver was referred for selective internal radionuclide therapy (SIRT) following a history of extensive systemic chemotherapy. 90Y PET imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. Lesion dosimetry was highly predictive of eventual response in the follow-up FDG PET performed 8 weeks after therapy. The derived radiation dose map was used to plan a second SIRT procedure aiming to protect healthy liver by keeping absorbed dose below the critical dose threshold, whilst targeting the remaining lesions that had received sub-critical dosing. Again, 90Y PET was performed immediately post-treatment and used to derive absorbed dose measures to both lesions and healthy parenchyma. Additional followup FDG PET imaging again confirmed the role of the 90Y PET dose map as an early predictor of response, and a tool for safe repeat treatment planning.
similar resources
changing therapeutic paradigms: predicting mcrc lesion response to selective internal radionuclide therapy (sirt) based on critical absorbed dose thresholds: a case study
a 65 year old male with metastatic colorectal cancer (mcrc) in the liver was referred for selective internal radionuclide therapy (sirt) following a history of extensive systemic chemotherapy. 90y pet imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. lesion dosimetry was highly predictive of eventual response in ...
full textIncreased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity
BACKGROUND The higher tolerated mean absorbed dose for selective internal radiation therapy (SIRT) with intra-arterially infused (90)Y microspheres compared to external beam therapy is speculated to be caused by absorbed dose inhomogeneity, which allows for liver regeneration. However, the complex liver microanatomy and rheology makes modelling less valuable if the tolerance doses are not based...
full textSummary and perspectives on kidney dose-response to radionuclide therapy.
The manuscripts included in this special issue of Cancer Biotherapy & Radiopharmaceuticals highlight current data and theoretical foundations regarding dose–response relationships related to radionuclide therapy kidney toxicity. With the use of the kidney dosimetry model presented in MIRD 19,1 these experimental and clinical data, when correlated with accurate regional dose information, may pro...
full textIntroduction to kidney dose-response for radionuclide therapy.
The proceedings of a MIRD-sponsored continuing medical education session entitled, “Kidney Dose–Response for Radionuclide Therapy,” held at the 50th Annual Meeting of the Society of Nuclear Medicine, in New Orleans in 2003, have been collected in this special section of Cancer Biotherapy & Radiopharmaceuticals. A few years ago, hematologic toxicity was the focus of concern in radionuclide thera...
full textEffect of image registration on 3D absorbed dose calculations in 177Lu-DOTATOC peptide receptor radionuclide therapy.
Peptide receptor radionuclide therapy (PRRT) is an effective MRT (molecular radiotherapy) treatment, which consists of multiple administrations of a radiopharmaceutical labelled with 177Lu or 90Y. Through sequential functional imaging a patient specific 3D dosimetry can be derived. Multiple scans should be previously co-registered to allow accurate absorbed dose calculations. The purpose of thi...
full textMy Resources
Journal title
volume 5 issue 1
pages 66- 69
publication date 2017-01-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023